Another clinically approved TMPRSS2 inhibitor, nafamostat, requires intravenous dosing and has also shown effect SARS-CoV-2 in vitro [39], but there isn’t any clinical study about the effectiveness of nafamostat for treating COVID-19 at the moment. Here, TMPRSS2 is linked to COVID-19.